KR20230107269A - 혈관부종의 예방 및 치료 - Google Patents

혈관부종의 예방 및 치료 Download PDF

Info

Publication number
KR20230107269A
KR20230107269A KR1020237018410A KR20237018410A KR20230107269A KR 20230107269 A KR20230107269 A KR 20230107269A KR 1020237018410 A KR1020237018410 A KR 1020237018410A KR 20237018410 A KR20237018410 A KR 20237018410A KR 20230107269 A KR20230107269 A KR 20230107269A
Authority
KR
South Korea
Prior art keywords
compound
acceptable salt
pharmaceutically acceptable
solvate
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018410A
Other languages
English (en)
Korean (ko)
Inventor
앤 르사쥬
펭 루
Original Assignee
파르바리스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르바리스 게엠베하 filed Critical 파르바리스 게엠베하
Publication of KR20230107269A publication Critical patent/KR20230107269A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237018410A 2020-11-12 2021-11-12 혈관부종의 예방 및 치료 Pending KR20230107269A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
EP20207273.2 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (1)

Publication Number Publication Date
KR20230107269A true KR20230107269A (ko) 2023-07-14

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018410A Pending KR20230107269A (ko) 2020-11-12 2021-11-12 혈관부종의 예방 및 치료

Country Status (13)

Country Link
US (1) US12629363B2 (cg-RX-API-DMAC7.html)
EP (1) EP4243824B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023549849A (cg-RX-API-DMAC7.html)
KR (1) KR20230107269A (cg-RX-API-DMAC7.html)
CN (1) CN116685353A (cg-RX-API-DMAC7.html)
AU (1) AU2021376885A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198246A1 (cg-RX-API-DMAC7.html)
ES (1) ES3061585T3 (cg-RX-API-DMAC7.html)
IL (1) IL302887A (cg-RX-API-DMAC7.html)
MX (1) MX2023005563A (cg-RX-API-DMAC7.html)
PL (1) PL4243824T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022101395A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305122B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025037920A1 (ko) 2023-08-16 2025-02-20 주식회사 엘지화학 수지 조성물

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
HRP20260166T1 (hr) * 2022-03-25 2026-03-27 Pharvaris Gmbh Čvrsti sastav koji sadrži solubilizirane antagoniste bradikinin b2 receptora

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249076A1 (en) 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. B2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) * 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025037920A1 (ko) 2023-08-16 2025-02-20 주식회사 엘지화학 수지 조성물

Also Published As

Publication number Publication date
JP2023549849A (ja) 2023-11-29
CN116685353A (zh) 2023-09-01
ZA202305122B (en) 2024-08-28
ES3061585T3 (en) 2026-04-06
WO2022101395A1 (en) 2022-05-19
EP4243824C0 (en) 2025-12-24
US20230338358A1 (en) 2023-10-26
IL302887A (en) 2023-07-01
PL4243824T3 (pl) 2026-05-18
MX2023005563A (es) 2023-09-11
EP4243824B1 (en) 2025-12-24
AU2021376885A1 (en) 2023-06-08
CA3198246A1 (en) 2022-05-19
US12629363B2 (en) 2026-05-19
EP4243824A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
TWI777515B (zh) 治療嗜伊紅性食道炎之方法
CN103974619B (zh) 治疗法布里病的给药方案
EP4243824B1 (en) Prophylaxis and treatment of angioedema
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
US20240197739A1 (en) Combination Comprising Ribociclib and Amcenestrant
US20230404971A1 (en) Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid
CN112789041A (zh) 用于降低血清尿酸的组合物
KR102766876B1 (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
CN108778266A (zh) 包含二高γ亚麻酸(DGLA)的医药组合物和其用途
TW202337469A (zh) 治療小細胞肺癌之方法
JPH11507012A (ja) 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
HK40099091A (en) Prophylaxis and treatment of angioedema
HK40099091B (en) Prophylaxis and treatment of angioedema
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
TW202122086A (zh) 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
KR19980702100A (ko) 심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제, 부작용-감소된 양의 알도스테론 길항제 및 이뇨제의 조합 치료요법
KR20240019265A (ko) Mmp-12 억제제의 안전한 투여
HK40058710A (en) Dosing regimens for the treatment of pompe disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000